Loading...
XNAS
EVGN
Market cap9mUSD
Dec 05, Last price  
1.11USD
1D
0.91%
1Q
-7.73%
Jan 2017
-78.24%
IPO
-90.21%
Name

Evogene Ltd

Chart & Performance

D1W1MN
XNAS:EVGN chart
P/E
P/S
1.14
EPS
Div Yield, %
Shrs. gr., 5y
-25.76%
Rev. gr., 5y
62.42%
Revenues
9m
+50.90%
14,901,00017,072,00017,581,00014,511,00011,129,0006,540,0003,381,0001,747,000753,0001,040,000930,0001,675,0005,640,0008,511,000
Net income
-16m
L-30.96%
645,000-2,522,000-8,878,000-14,530,000-17,213,000-19,592,000-20,838,000-20,758,000-18,112,000-23,374,000-27,793,000-26,638,000-23,879,000-16,485,000
CFO
-20m
L-8.70%
2,133,000-1,888,000-5,270,000-8,895,000-12,407,000-11,693,000-15,929,000-15,161,000-17,364,000-19,514,000-24,839,000-23,678,000-21,577,000-19,700,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged through big data and artificial intelligence, designed to computationally discover and uniquely guide the development of life-science products based on microbes, small molecules, and genetic elements. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and antimicrobial resistance organisms. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer; and through its subsidiary, Canonic Ltd., has a collaboration agreement with Cannbit Ltd. for the development of novel medical cannabis products. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.
IPO date
Jun 11, 2007
Employees
137
Domiciled in
IL
Incorporated in
IL

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT